CV Sciences Eagerly Anticipating FDA Rulemaking On CBD In Dietary Supplements
Duffy MacKay, senior VP of scientific and regulatory affairs at CV Sciences, offers his predictions regarding the FDA’s likely course in regulating CBD’s use in dietary supplements – action that is sorely needed as the market continues to crowd with CBD products “with who-knows-what in them.”
You may also be interested in...
Perrigo leads major consumer health companies into the CBD space with its $50m investment in Kazmira LLC, a Colorado business. The firm says the companies will lay groundwork for quality standards in the CBD market.
Charlotte’s Web is strengthening its DTC lead while growing its brick-and-mortar retail business, accelerating its pet product distribution and working to close its Abacus Health acquisition announced in March. The Boulder, CO-based CBD product manufacturer posted a 1% decline in net sales for the first quarter, but expects a rapid escalation in the second half of the year.
Store closures in the natural product channel did no favors for CV Sciences in March, but the 45% decrease in its first-quarter sales reflects pressures that were weighing on its consumer business before the pandemic struck. The PlusCBD product manufacturer remains confident about its long-term prospects in what it expects to be a more sensibly regulated marketplace versus the status quo.